A Keytruda Patient Running the 2022 Chicago Marathon

My training began last week for the 2022 Bank of America Chicago Marathon. That’s not that unusual; this year’s Chicago Marathon will have approximately 45,000 participants. What’s different about my story is I am currently a Keytruda patient under treatment for inoperable Stage IV non-small cell lung cancer.
The diagnosis came in early October 2020, immunotherapy treatment with Keytruda began later that same month and by the end of April 2021 – six months later – there was no longer any significant evidence of disease. That’s immunotherapy in, perhaps, a best-case scenario but it is reality and that’s where we are with cancer treatment today. We need to spread the word about how much progress has been made. A Keytruda patient participating in the 2022 Chicago Marathon sends a pretty clear message about the state of cancer treatment today.